Genfit (NASDAQ:GNFT) Stock Price Up 2.1% – What’s Next?

Shares of Genfit S.A. (NASDAQ:GNFT) traded up 2.1% during mid-day trading on Monday . The company traded as high as $3.50 and last traded at $3.46. 2,869 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 14,448 shares. The stock had previously closed at $3.39.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Genfit in a report on Friday, February 7th.

Genfit Price Performance

The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61. The business has a 50 day simple moving average of $3.58 and a 200-day simple moving average of $4.17.

Institutional Investors Weigh In On Genfit

A hedge fund recently bought a new stake in Genfit stock. Millennium Management LLC purchased a new stake in Genfit S.A. (NASDAQ:GNFT) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned 0.33% of Genfit at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.24% of the company’s stock.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.